ライフサイエンスコーパス: blind trial

1 in a randomized, placebo-controlled, double-blind trial.

2 r placebo (n = 31) for 7 days in this double-blind trial.

3 has not been studied in a controlled, double-blind trial.

4 (TEAR) study is a 2-year, randomized, double-blind trial.

5 in a randomized, placebo-controlled, double-blind trial.

6 Pilot single-blind trial.

7 ntre, randomised, placebo-controlled, double-blind trial.

8 o GA or placebo (PBO) in this 3-year, double-blind trial.

9 ed, multi-center, placebo-controlled, double-blind trial.

10 in a placebo-controlled, randomized, double-blind trial.

11 mg FeSO(4) or a placebo for 6 wk in a double-blind trial.

12 (1000 mg per day) or to placebos in a double-blind trial.

13 r a placebo twice daily for 6 wk in a double-blind trial.

14 oxetine were assessed after a 6-week, double-blind trial.

15 lacebo, during the subsequent 28-week double-blind trial.

16 illary thermotherapy in a randomized, double-blind trial.

17 wal, multicenter, placebo-controlled, double-blind trial.

18 llel-group, randomised, controlled, observer-blind trial.

19 tions) was a prospective, randomized, double-blind trial.

20 nce were entered into this crossover, double-blind trial.

21 re and reduced ejection fraction in a double-blind trial.

22 e based on the results of randomized, double-blind trials.

23 daily for 6 or 9 months in 4 similar double-blind trials.

24 ings from open-label series and small double-blind trials.

25 prospective, randomized, multicenter, single-blinded trial.

26 s with up to 90% accuracy in an independent, blinded trial.

27 ction in a single center, randomized, double-blinded trial.

28 orrectly classified 9 of 10 chemicals in the blinded trial.

29 any different AEs have been reported than in blinded trials.

30 g permuted-block randomisation in non-double-blinded trials.

31 In a single-blind trial, 106 individuals with TMJ closed lock were r

32 In a double-blind trial, 157 inpatients with a history of suboptimal

33 In a three-year, double-blind trial, 160 patients with coronary disease, low HDL

34 In a randomized controlled blinded trial, 2-year-old purpose-bred beagles (n = 24),

35 control.In a randomized, controlled, double-blinded trial, 220 participants aged 18-60 y with body m

36 In a double-blind trial, 225 adults underwent randomization.

37 In this randomized, 2 x 2 factorial, double-blind trial, 2400 infants were randomly assigned to rece

38 this randomized, placebo-controlled, double-blind trial, 25 patients were treated with either sorivu

39 multicenter, randomized, controlled, double-blind trial, 340 HIV-1-positive adults not on antiretrov

40 In a double-blind trial, 499 patients aged 14 years or older admitte

41 Data were pooled from 10 double-blind trials (6699 patient-years of follow-up).

42 In a double-blind trial, 73 patients (median age, 63 years; 29% wome

43 In a prospective, double-blind trial, acute liver failure patients without clinic

44 In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, >/=12 y

45 In a randomized, double-blind trial, adults with acute bacterial skin and skin s

46 e assay was also successfully evaluated in a blind trial against analysing 60 samples from different

47 In a 12-week randomized, double-blind trial, ALS and MS patients with clinically signifi

48 (N=50) or placebo (N=53) in a 9-week double-blind trial and 4-week follow-up assessment.

49 seline, 232 completed 52 weeks of the single-blind trial and met response criteria.

50 Salaam, Tanzania, were enrolled in a double-blind trial and provided daily supplements of preformed

51 ow-income settings: concerns associated with blinded trials and the need for objective outcomes.

52 Larger scale, randomized, double-blind trials are needed to validate the role of statins

53 This randomized double-blind trial assessed the potential additional impact of

54 first placebo controlled, randomized double blinded trial assessing the efficacy and tolerability of

55 did a randomised, placebo-controlled, double-blind trial at 29 UK secondary and tertiary hospitals of

56 We performed a double-blind trial at a tertiary care hospital in India.

57 We did this multicentre, double-blind trial at four general hospitals in northern Italy.

58 rallel-treatment, placebo-controlled, double-blind, trial at 81 sites in the Europe and the USA, adul

59 nducted a prospective, randomized, evaluator-blinded trial at three medical centers.

60 t pairs were enrolled in a randomised double-blind trial between September, 2001, and October, 2004,

61 In this multicentre, double-blind trial, between Oct 21, 2013, and Oct 30, 2014, we

62 G) conducted a randomized, phase III, double-blind trial, BIG 1-98, which enrolled 8,010 postmenopaus

63 Two phase 3 multicenter, randomized, double-blind trials carried out from 2007 to 2010.

64 In this parallel placebo-controlled double-blinded trial, children aged 3-12 years with >4 weeks of

65 This randomized, double-blind trial compared a regimen of 7 to 12 days of oral x

66 A 3-week, randomized, double-blind trial compared flexibly dosed olanzapine (5-20 mg/

67 This multicenter, randomized, double-blind trial compared fluconazole (N = 295) versus vorico

68 Randomized, controlled, double-blind trial compared RRR-alpha-tocopherol (1200 IU/d for

69 This randomized double-blind trial compared the impact of PCV13 versus PCV7 on

70 We conducted a randomized, double-blind trial comparing a sirolimus-eluting stent with a s

71 eview Board (IRB)-approved randomised double-blind trial comparing active to sham deep brain stimulat

72 A 24-week randomized double-blind trial comparing ALC (3,000 mg per day) with placeb

73 We performed a post hoc analysis of a double-blind trial comparing fondaparinux with placebo.

74 prospective, randomized, multicenter, double-blind trial comparing polymer-free SES with placebo-coat

75 We conducted a randomized, double-blind trial comparing salmeterol at a dose of 50 microg

76 The study was a randomized, double-blind trial conducted at 30 hemodialysis units at Vetera

77 /2, dose-finding, placebo-controlled, double-blind trial conducted at the University Hospitals of Gen

78 Randomized, double-blind trial conducted in 3 sites in the Pacific Northwes

79 In a randomized, double-blind trial conducted in 399 adults > or = 65 years of a

80 In this double-blind trial conducted on Pemba Island, Tanzania, we rand

81 Design: A cluster randomized blinded trial conducted between October 2012 and May 201

82 EAN study was a randomized controlled single-blind trial (CPP 2009-A00346-51).

83 As a proof of concept, using a single-blind trial design, we evaluated the progress of 45 pati

84 ME-Meso is a phase II/III randomized, double-blind trial designed to assess efficacy and safety of ni

85 nter, randomized, placebo-controlled, double-blind trial designed to determine the effect of three ye

86 This blinded trial did not show a significant reduction of sy

87 ed in a randomized placebo-controlled double-blind trial (Eastern Cooperative Oncology Group 3999).

88 In a multicenter, double-blind trial, eligible adults with acute pericarditis wer

89 This randomized clinical double-blind trial enrolled participants at 2 clinical sites in

90 Blinded trials enrolled significantly more patients and

91 A randomized, double-blind trial evaluated citalopram at target doses of 10,

92 III, randomized, placebo-controlled, double-blind trial evaluated gefitinib plus paclitaxel and carb

93 This randomized, double-blind trial evaluated the efficacy and safety of 16 week

94 This double-blind trial evaluated the safety and efficacy of a human

95 tation) was a randomized, controlled, double-blind trial evaluating the effect of etanercept versus p

96 Results from a government-managed blind trial evaluation of the signature library demonstr

97 nd the first prospective, randomized, double-blind trials ever performed in transplantation.

98 DESIGN, SETTING, AND PARTICIPANTS: Double-blind trial examining changes in the neural circuits inv

99 In two phase 3, double-blind trials (EXPEDITION 1 and EXPEDITION 2), we randoml

100 was modest (NNT=17), but confirmed in double-blind trials, first- and multi-episode patients, using p

101 IMT (n = 38) or placebo (n = 37) in a double-blind trial for six months, with continuation of standar

102 The blinded trials found no significant reduction in blood p

103 Few double-blind trials have compared longer-term efficacy and safe

104 Few blinded trials have compared conventional therapy consis

105 We did a parallel-group, randomised, double-blind trial in 11 secondary and two primary care sites i

106 in a placebo-controlled, randomized, double-blind trial in 60 patients with bipolar depression, with

107 In a double-blind trial in Dar es Salaam, Tanzania, we randomly assi

108 This study was a randomized, double-blind trial in patients aged >18 years with ABSSSIs.

109 ormed a 15- to 24-month, multicenter, double-blind trial in patients with advanced Parkinson disease

110 This was a 39-center, double-blind trial in patients with definite MS of any course t

111 ook a randomised, placebo-controlled, double-blind trial in three South African sites in sexually-act

112 nopausal women participated in a 6-mo double-blind trial in which 40 g protein as part of a National

113 We conducted a randomized, double-blind trial in which adults with acute bacterial skin an

114 ENGAGE AF-TIMI 48 was a randomised, double-blind trial in which patients with atrial fibrillation w

115 e 2, multicentre, placebo-controlled, double-blind trials in patients with advanced or incurable canc

116 d a pooled analysis of data from four double-blind trials in which 1748 patients were randomly assign

117 nt-level database from 4 prospective, double-blind trials in which 3445 patients were randomized to p

118 stents or bare-metal stents and five double-blind trials in which 3513 patients were randomly assign

119 in a randomized, placebo-controlled, double-blinded trial in 110 human immunodeficiency virus-serone

120 ecimens obtained during a randomized, double-blinded trial in antiretroviral therapy (ART)-naive HIV-

121 We did this non-blinded trial in two National Health Service (NHS) regio

122 This monocentric, placebo-controlled, double-blind trial included 132 patients with grass pollen-indu

123 This randomised double-blind trial included 9270 patients with chronic kidney d

124 unity-based, prospective, randomized, double-blind trial including 1702 men and women with no prior h

125 In a randomized, multicenter, double-blind trial, inhaled iloprost (5 mug) or placebo was add

126 were enrolled in a placebo-controlled double-blind trial investigating the effects of growth hormone

127 In a randomized, double-blind trial involving 135 patients with severe eosinophi

128 e Pediatric Heart Network conducted a double-blind trial involving 230 infants with single-ventricle

129 We conducted a 56-week, double-blind trial involving 3731 patients who did not have typ

130 conducted a multicenter, randomized, double-blind trial involving nulliparous women who were at low

131 conducted a multicenter, prospective, double-blind trial involving outpatient adults and children.

132 In a double-blind trial involving patients with end-stage renal dise

133 In two multicenter, randomized, double-blind trials involving 448 patients with ARDS from vario

134 lacebo-controlled, participant- and assessor-blinded trial involving 102 community volunteers with hi

135 For non-double-blinded trials larger than 200 participants, investigato

136 Five randomized double-blind trials lasted 12-16 weeks and treated 1,293 patien

137 We conducted a long-term, double-blind trial (mean follow-up, 4.5 years) involving 3047 m

138 ents exposed to ranolazine during the double-blind trials (n = 972) preceding the ROLE program, annua

139 were initially randomly assigned to a double-blind trial of 12 once-weekly subcutaneous injections of

140 We performed a double-blind trial of 204 patients (78% Caucasian; 67% female;

141 N, SETTING, AND PATIENTS: Randomized, double-blind trial of 300 women aged 18 to 55 years with acute

142 nducted a single-center, prospective, double-blind trial of 39 patients with mucinous-type pancreatic

143 e were randomly assigned to a 28-week double-blind trial of 50-200 mg/day of sertraline or placebo.

144 in a randomized, placebo-controlled, double-blind trial of a nonselective beta-blocker used to preve

145 arge, randomized, placebo-controlled, double-blind trial of a statin with standard-of-care for patien

146 We performed a prospective double-blind trial of adult patients with a recent (<8 weeks) d

147 n a national multicenter, randomized, double-blind trial of an acellular pertussis vaccine.

148 As part of a randomized, double-blind trial of antifungal prophylaxis in liver transplan

149 A multicenter, randomized, double-blind trial of aspirin (300 mg/day) and folate supplemen

150 We performed a randomized, double-blind trial of aspirin as a chemopreventive agent agains

151 sion In this prospective, randomized, double-blind trial of ATLG in unrelated myeloablative HCT, the

152 prospective, multicenter, randomized, double-blind trial of early CCS withdrawal in 386 kidney transp

153 orty-six CAE children in a randomized double-blind trial of ethosuximide, lamotrigine, and valproate

154 In a randomized, placebo-controlled, double-blind trial of exemestane designed to detect a 65% relat

155 year, randomized, placebo-controlled, double-blind trial of intra-articular triamcinolone vs saline f

156 in a randomized, placebo-controlled, double-blind trial of levofloxacin (P = .01).

157 ed sunitinib therapy in a randomized, double-blind trial of metastatic castration-resistant prostate

158 nter, randomized, placebo-controlled, double-blind trial of New York Heart Association class II to IV

159 We performed a phase 3, double-blind trial of patients who completed golimumab inductio

160 We then performed a double-blind trial of patients with IBS (mean age, 31 y; range,

161 onducted a single-center, randomized, double-blind trial of perioperative subcutaneous pasireotide in

162 nter, randomized, placebo-controlled, double-blind trial of placebo versus nasal mometasone in adults

163 BIG 1-98 is a randomised, phase 3, double-blind trial of postmenopausal women with hormone recepto

164 na) was an international, randomized, double-blind trial of ranolazine versus placebo in patients wit

165 conducted a prospective, randomized, double-blind trial of rifapentine at three doses (600, 900, and

166 We conducted a multisite, randomized, double-blind trial of risperidone as compared with placebo for

167 r response after 16 and 52 weeks of a single-blind trial of sertraline were randomly assigned to a 28

168 om a previously reported, randomized, double-blind trial of standard- versus low-dose lithium for mai

169 did a randomised, placebo-controlled, double-blind trial of the effect of intermittent preventive tre

170 performed a multicenter, randomized, double-blind trial of the efficacy and safety of 400, 800, and

171 jects, randomized, placebo-controlled double-blind trial of the nicotinic agonist AZD3480 (also terme

172 We conducted a placebo-controlled, double-blind trial of the prophylactic effect of vitamin A on g

173 nrolled in a prospective, randomized, double-blind trial of traumatic hypovolemic shock, HSD (250 mL)

174 gust 2010, we conducted a randomized, double-blind trial of twice daily 500 mg valacyclovir or placeb

175 in a randomized, placebo-controlled, double-blind trial of up to three 26-day courses of treatment w

176 cruited for a randomized, controlled, double-blind trial of vitamin D supplementation in pregnancy (4

177 bran fiber (WBF) study, a randomized, double-blind trial of WBF as a means of decreasing the probabil

178 data from two replicate, randomised, double-blind trials of 12 months' duration (Sept 25, 2009 to Oc

179 nsored randomised placebo-controlled, double-blind trials of 75 mg twice a day oseltamivir in adults.

180 ing the major investment required for double-blind trials of a potential disease-modifying drug in PD

181 id three phase 1, placebo-controlled, double-blind trials of ZPIV with aluminium hydroxide adjuvant.

182 allel, 3-group, placebo-controlled, multiply-blinded trial of 342 adults with mild to moderate asthma

183 pragmatic, multicenter, randomized, observer-blinded trial of 734 high-risk patients aged 50 years or

184 ted a placebo-controlled, randomized, double-blinded trial of alendronate (10 mg/day orally) (n = 24)

185 who had participated in a randomized, single-blinded trial of an undiluted or a 1 : 5 or 1 : 10 dilut

186 e of this study was to examine outcomes of a blinded trial of initial MTX monotherapy with the option

187 Randomized, blinded trial of intramuscular gene transfer using plasm

188 performed a randomized, placebo-controlled, blinded trial of low-dose (0.5 mg/kg) or high-dose (2 mg

189 After a 1-month blinded trial of patient-assessed twice-per-week tampon

190 One-year results of a randomized, double-blinded trial of Thymoglobulin versus Atgam for inductio

191 overcome the shortcomings of previous double-blinded trials of household water treatment in low-incom

192 Meta-analyses of blinded trials of non-drug treatments have not yet prove

193 safety and efficacy data in numerous large, blinded trials on adult patients have led to increasing

194 In this randomized, double-blind trial, outpatients with schizophrenia (n=55) recei

195 parallel-group design, patient- and observer-blinded trial patients undergoing open elective abdomina

196 In this phase 3, randomised, double-blind trial, patients were enrolled across 141 sites in

197 In this double-blind trial, patients were randomized to receive daily o

198 In a double-blind trial, patients were randomized to tolvaptan 30 mg

199 In this phase 3, double-blind trial, patients were randomly assigned (1:1) to re

200 In this phase 3, double-blind trial, patients were randomly assigned (2:1) to re

201 These three multicenter, prospective, double-blind trials performed at 55 transplant centers on three

202 se 3, randomized, placebo-controlled, double-blind trials performed from July 15, 2010, to April 16,

203 (Dual Antiplatelet Therapy) Study, a double-blind trial, randomly assigned 11 648 patients who had u

204 In the blind trial set, the panel correctly classified 93.33% A

205 are no large, prospective, randomized double-blind trials testing the efficacy of IE prophylaxis.) Ho

206 was a randomized, placebo-controlled, double-blind trial that assessed the effects of fludrocortisone

207 with a COX-2 selective inhibitor in a double-blind trial that compared placebo, low-dose aspirin, rof

208 IMI 56 was a multicenter, randomized, double-blind trial that enrolled and genotyped 333 patients wit

209 The BIG 1-98 trial is a double-blind trial that randomly assigned 6,193 postmenopausal

210 ial was an international, randomised, double-blind trial that recruited patients with unresectable st

211 This study is the first to demonstrate in a blinded trial that initial MTX monotherapy with the opti

212 r participation, and suggest alternatives to blinded trials that could resolve continued uncertainty

213 In this double-blind trial, the infants were randomly assigned to 1 of

214 of data from randomized, prospective, double-blind trials, the effect of n-3 fatty acids on depressio

215 In blinded trials, the call rate for the eight most common

216 In a blind trial, this sPMCA-based assay specifically amplifi

217 We did a randomised, double-blind trial to assess the usefulness of sibutramine in m

218 We undertook a single-blind trial to assess this approach.

219 ted a randomized, placebo-controlled, double-blind trial to assess whether use of the selective COX-2

220 Subjects were randomized in this double-blind trial to atorvastatin 80 mg/d or placebo for 16 we

221 We undertook a randomised double-blind trial to compare the effectiveness of chlorampheni

222 We did a phase 1 double-blind trial to compare the safety and immunogenicity of

223 We conducted a randomized, double-blind trial to determine the effect of aspirin on the in

224 ted a randomized, placebo-controlled, double-blind trial to establish the efficacy of atovaquone-prog

225 We conducted a randomized, double-blind trial to evaluate intravenous benzodiazepines admi

226 conducted an exploratory, randomized, single-blind trial to evaluate the efficacy and safety of moxid

227 formed a placebo-controlled, phase 3, double-blind trial to evaluate the efficacy and safety of vedol

228 Recurrent Stroke Study, a randomized double-blind trial to evaluate the efficacy of warfarin compare

229 tin 80 mg vs. 10 mg in a multicenter, double-blind trial to evaluate the impact of atorvastatin on ar

230 We conducted a double-blind trial to evaluate this therapeutic approach.

231 We conducted a randomized, double-blind trial to examine the effect of celecoxib on drug-s

232 ting component terms, and we propose further blind trials to test such efforts.

233 may encourage control group participants in blinded trials to cease practicing traditional water tre

234 Randomized, double-blind trial (treatment period, 18 months; median follow-

235 is multicenter, randomized, partially double-blind trial used a factorial design to compare pairs of

236 or the 60 training compounds and an unbiased blinded trial using a single hold-out set of 10 addition

237 A randomized, double-blind trial was conducted at ambulatory care centers at

238 A randomized, double-blind trial was conducted in 189 volunteers aged 50-85 y

239 A randomized, double-blind trial was conducted in 4 countries (Afghanistan, D

240 dialysis, a multicenter, randomized, double-blind trial was conducted in 92 patients (control, 45; i

241 This prospective, randomized, double-blind trial was conducted to compare clinafloxacin with

242 spective, randomized, controlled, and double-blind trial was conducted to compare the safety and effi

243 The double-blind trial was terminated early because buprenorphine a

244 This double-blind trial was undertaken in 255 sites in 30 countries.

245 , sham-controlled, rater-blinded and patient-blinded trial was conducted from 2007-2011.

246 This parallel group, semirandomized double-blinded trial was conducted in a single center in the Un

247 A prospective, randomized (1:1), double-blinded trial was conducted with 100 subjects.

248 A randomized-order, crossover, double-blinded trial was performed in 14 healthy postmenopausal

249 A double-blinded trial was performed involving 29 nonhypoxemic pa

250 802, a phase 3 multicenter randomized double-blinded trial, was designed to test whether mycophenolat

251 In this 52-week, randomized, double-blind trial, we assessed efficacy and augmentation in pa

252 In this randomized, double-blind trial, we assessed the efficacy and safety of anti

253 In a randomized, double-blind trial, we assigned 11,506 patients with hypertensi

254 In this randomized, double-blind trial, we assigned 2278 patients with systolic hea

255 In this randomized, double-blind trial, we assigned 3445 patients with symptomatic

256 ternational, multicenter, randomized, double-blind trial, we assigned critically ill adults to receiv

257 In this randomized, double-blind trial, we compared 4 years of therapy with either

258 In this randomized, double-blind trial, we compared apixaban (at a dose of 5 mg twi

259 In this randomised, double-blind trial, we compared degree of pain between standard

260 In this randomized, double-blind trial, we compared parenteral amiodarone, lidocain

261 In a randomized, double-blind trial, we compared tenecteplase plus heparin with

262 In a randomized, double-blind trial, we compared the drug-coated stent with a ve

263 In a double-blind trial, we compared the effect of the angiotensin-r

264 In our prospective randomised double-blind trial, we enrolled adults (>40 years) with karyoty

265 ternational, multicentre, randomised, double-blind trial, we enrolled patients aged 18-65 years with

266 se 2, placebo-controlled, randomized, double-blind trial, we evaluated a vaccine consisting of recomb

267 In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of ora

268 In this double-blind trial, we examined the possibility that rasagiline

269 In a prospective, multicenter, double-blind trial, we randomized 2,466 high bleeding risk pati

270 In a two-site, double-blind trial, we randomized 42 adult patients with stage

271 In a double-blind trial, we randomly assigned 14,264 patients with n

272 In a double-blind trial, we randomly assigned 15,828 patients with s

273 In a three-month, double-blind trial, we randomly assigned 209 patients with shif

274 In this double-blind trial, we randomly assigned 2157 patients with acu

275 In this double-blind trial, we randomly assigned 225 men over the age o

276 In this multicenter, double-blind trial, we randomly assigned 3876 patients who had

277 In this double-blind trial, we randomly assigned 8442 patients with cla

278 In a randomized, double-blind trial, we randomly assigned a total of 213 patient

279 In this double-blind trial, we randomly assigned patients with intermed

280 In this double-blind trial, we randomly assigned patients with type 2 d

281 this multicenter, placebo-controlled, double-blind trial, we randomly assigned women at imminent risk

282 In this phase 3, randomised, double-blind trial, we recruited eligible patients with histolo

283 nter, placebo-controlled, randomized, double-blind trial, we showed that acquired infections in intub

284 In two double-blind trials, we randomly assigned patients to receive s

285 women participating in a randomized, double-blinded trial, we assessed the effect of periodic presum

286 In this multicenter, randomized, blinded trial, we assigned critically ill adults to rece

287 In this multicenter, parallel-group, blinded trial, we randomly assigned patients with severe

288 In this randomised, multi-institutional, non-blinded trial, we randomly assigned patients with spinal

289 Primary outcomes after the double-blind trial were full relapse, dropout due to relapse or

290 prospective, randomized multicenter, double-blind trial were to compare the efficacy of the micro-em

291 The results from 2 parallel-design, double-blind trials were combined.

292 Two phase 3 randomized, double-blind trials were conducted at 154 sites in the United S

293 OCD youth-in a randomized rater-blinded trial-were re-scanned after 12-14 weeks of CBT o

294 harov and colleagues did a randomised double-blind trial which showed that training by virtual realit

295 In this phase 3, double-blind trial, which was conducted at 133 centers worldwid

296 med a randomized, placebo-controlled, double-blind trial with 48 obese participants and used function

297 In this eight-center, randomized, double-blind trial with a 2-by-2 factorial design, we compared

298 miodarone, a multicenter, randomized, double-blind trial with cardiovascular outcomes that compares a

299 l bleeding in a prospective, phase 3, double-blind trial with parallel omeprazole suspension and cime

300 We conclude that double-blinded trials with consistent application of measuremen